Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 6/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28838633 | 1.00 | ALDH1A1 (0.43) | ALDH1A1GAAHTTNPC1LMNA | |
| SCHEMBL5166307 | 1.00 | ALDH1A1 (0.43) | ALDH1A1GAAHTTNPC1LMNA | |
| SCHEMBL5371795 | 1.00 | ALDH1A1 (0.43) | ALDH1A1GAAHTTNPC1LMNA | |
| SCHEMBL874439 | 1.00 | ALDH1A1 (0.43) | ALDH1A1GAAHTTNPC1LMNA | |
| SCHEMBL874440 | 1.00 | ALDH1A1 (0.43) | ALDH1A1GAAHTTNPC1LMNA | |
| SCHEMBL23298241 | 1.00 | ALDH1A1 (0.43) | ALDH1A1GAAHTTNPC1LMNA | |
| SCHEMBL874438 | 1.00 | ALDH1A1 (0.43) | ALDH1A1GAAHTTNPC1LMNA | |
| SCHEMBL6951727 | 0.85 | NPC1 (0.43) | ALDH1A1GAAHTTNPC1LMNA | |
| SCHEMBL3117948 | 0.85 | ALDH1A1 (0.43) | ALDH1A1GAAHTTNPC1LMNA | |
| SCHEMBL6950966 | 0.85 | NPC1 (0.43) | ALDH1A1GAAHTTNPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656963-B2 | Dihydropyrazole GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-9604964-B2 | Dihydropyrazole GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2925726-B1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2925749-B1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160297797-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-13 | — | — | US | disclosed |
| US-20160280659-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-09-29 | — | — | US | disclosed |
| EP-2920165-B1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2925726-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2015-10-07 | — | — | EP | disclosed |
| EP-2925749-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2015-10-07 | — | — | EP | disclosed |
| EP-2920165-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2015-09-23 | — | — | EP | disclosed |
| US-9133163-B2 | Dihydropyrazole GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2771345-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | Merck Sharp & Dohme Corp. (US) | 2014-09-03 | — | — | EP | disclosed |
| US-20140142139-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-22 | — | — | US | disclosed |
| WO-2014078610-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078611-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078608-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2013063217-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| US-7309714-B2 | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-12-18 | — | — | US | disclosed |
| US-20060111336-A1 | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280659-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | GPR55, GPR35, GPR65 | ALDH1A1 1544/4885GAA 4063/4885HTT 4054/4885 |
| US-20160297797-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | GPR55, GPR65, GPR35 | ALDH1A1 1408/4885GAA 3939/4885HTT 3757/4885 |
| US-20140142139-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | GPR55, GPR35, GPR65 | ALDH1A1 1544/4885GAA 4063/4885HTT 4054/4885 |
| US-20060111336-A1 | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | ALDH1A1 984/4885GAA 129/4885HTT 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.